2023 EBMT-EHA: Encouraging initial safety and efficacy data for point-of-care manufactured GLPG5201 CAR-T in rrCLL presented

“We were very pleased to present strong initial data from the ongoing Phase 1/2 study of our fresh CD19 CAR-T candidate manufactured at point-of-care. This marks an important milestone in our journey to transform the lives of patients with severe blood cancers, including patients with RT, through the acceleration of innovation and breakthrough science”, said Dr. Paul Stoffels1, CEO of Galapagos. “We look forward to reporting Phase 1 topline data around mid-year.”
Share:
More News
CEO Snehal Patel commented, “We are very encouraged to see that the preliminary results from FLAMINGO-01 show immune responses in both HLA-A*02 and non-HLA-A*02 patients. We are now considering the merits of adding a randomized placebo arm for non-HLA-A*02 patients, transforming this current open label third arm into effectively a
“At Ferring, we are committed to meeting the unmet needs in bladder cancer care and equipping uro-oncologists with critical evidence they need to deliver effective, and life-changing treatment,” said Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals. “These new
“We recognise the significance of Mosaic’s platform, which has identified these two assets as anchor components of a pipeline of potential combination products,” said Dr. Harren Jhoti, co-founder, president and chief executive officer of Astex. “Both drug targets are well-characterised drivers of many cancers, and we are excited to be
“We do not view today’s unsatisfactory outcome as a failure of Globo H,” Dr. Heidi Wang, CEO of OBI Pharma added. “There may come a time, with a deeper scientific understanding of the Globo H function, it may play a meaningful role once again.”